Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label Study of the Safety and Efficacy of Multi- Vessel Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With Cardiomyopathy Secondary to Duchenne Muscular Dystrophy

Trial Profile

A Randomized, Open-label Study of the Safety and Efficacy of Multi- Vessel Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With Cardiomyopathy Secondary to Duchenne Muscular Dystrophy

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deramiocel (Primary)
  • Indications Cardiomyopathies; Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Acronyms HOPE-1; HOPE-DUCHENNE
  • Sponsors Capricor

Most Recent Events

  • 09 Jan 2025 Phase of the study was changed from phase 1/2 to phase 2, hence the protocol was amended.
  • 24 Jan 2019 According to a Capricor Therapeutics media release, results of this study were published in the 23rd Jan 2019, online issue of Neurology, the medical journal of the American Academy of Neurology.
  • 24 Jan 2019 Results presented in a Capricor Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top